SITE MANAGEMENT ORGANIZATION (SMO)

ACE Research SMO: Excellence in Site Management for African Clinical Trials

The ACE Research Site Management Organization program provides access to over 400 community-based public, private, and non-profit hospitals in Africa with modern facilities, expediting your clinical research program.

  • Access multiple sites through one central SMO.
  • Simply multisite communication through a single contact.
  • Streamline administrative and operational workflow.
  • Standardize quality oversight, Safety, and SOPs
  • Rapid multiple clinical sites start-up and activation
Site Management organization
Site Management Organization

TACKLING INEFFICIENCIES IN SITE MANAGEMENT

The Conventional Approach to Site Management is fragmented

This leads to increased sponsor oversight, prolonged timelines, increased costs, and potential risks to patient safety and data integrity.

MAXIMIZING SITE MANAGEMENT EFFICIENCY AND COMPLIANCE

We’re setting new benchmarks in efficiency and quality for African clinical research.

GCP Compliance and Audit

Successful US FDA and regulatory authorities audit due to robust quality control and effective management practices at the trial site.

Networked Sub-Saharan Africa Hospitals

400+

Patients Accessed Annually

520k

Patient Recruitment

Mean 97%

  • Strong patient engagement programs

  • Defined community demographics

  • Prescreened patient databases

WHY CHOOSE ACE RESEARCH SMO

We offer one-of-a-kind Site Management Organization (SMO) services improving relationships with African research sites and investigators and facilitating effective site-sponsor interactions.

  • Simplified, centralized access to multiple sites.

  • Staffing – Hire, train and compensate site employees
  • Centralized PI/site training – Protocol, SOPs, GCP
  • Centralized Study Start-Up and CTAs
  • Dedicated patient recruitment professionals.

  • Clinical supplies inventory management from a single interface.

  • Standardize SOPs and quality metrics

  • Scientific and resource support for investigator-initiated trials